Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XTL-001
- Development stage
- Discontinued
- Lead developer
- XTL Biopharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**XTL-001** is an investigational fixed-combination passive immunotherapy comprising the fully human anti-hepatitis B surface antigen monoclonal antibodies **exbivirumab** and **libivirumab**. The antibodies bind distinct epitopes on hepatitis B virus surface antigen, neutralizing circulating virus and reducing the potential for escape variants. XTL Biopharmaceuticals developed the product for chronic hepatitis B virus infection and prevention of hepatitis B virus reinfection after liver transplantation; Cubist later licensed and advanced the program. The program reached Phase II studies but was discontinued after Cubist ended the license agreement in July 2007.
- Brand names
- HepeX-B
- Other names
- ABXTLexbivirumab + libivirumabHBV-AB XTLHepeX-Blibivirumab + exbivirumabXTL001 monoclonal antibodyXTL-001 monoclonal antibodyXTL 001 monoclonal antibody
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on XTL-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XTL-001.